

Editorial



A New Prognostic Tool for Korean Patients with Acute Myocardial Infarction

Hyeon Chang Kim , MD^{1,2}

¹Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea

²Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

OPEN ACCESS

Received: Apr 11, 2018

Accepted: Apr 18, 2018

Correspondence to

Hyeon Chang Kim, MD

Department of Preventive Medicine, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
E-mail: hckim@yuhs.ac

Copyright © 2018. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Hyeon Chang Kim 

<https://orcid.org/0000-0001-7867-1240>

Conflict of Interest

The author has no financial conflicts of interest.

The contents of the report are the author's own views and do not necessarily reflect the views of the *Korean Circulation Journal*.

► See the article "Risk Scoring System to Assess Outcomes in Patients Treated with Contemporary Guideline-Adherent Optimal Therapies after Acute Myocardial Infarction" in volume 48 on page 492.

Cardiovascular diseases (CVDs), especially acute myocardial infarction (AMI), are among the leading causes of morbidity and mortality worldwide.¹⁾ Therefore, prediction of developing AMI in the general population and prediction of prognosis in patients with AMI are ongoing areas of research.²⁾ The first challenge faced by precision medicine in CVD is to identify individuals at high risk for AMI and to seek personalized prevention strategies.³⁾ However, predicting mortality or recurrence in patients who have already developed AMI is no less important. Since patients who survive AMI are at risk of developing another cardiac event or death, we need to identify high-risk AMI patients and employ aggressive prevention strategies in these individuals.

An increasing number of studies have sought to predict CVD in the Korean population⁴⁻⁶⁾ and to predict prognosis in Korean patients with AMI.⁷⁻⁹⁾ In this issue of the *Korean Circulation Journal*, Song et al.¹⁰⁾ reports a new risk score, the Korea Working Group in Myocardial Infarction (KorMI) system, to predict one-year adverse outcomes among AMI patients being treated with guideline-adherent optimal therapies. The newly-developed KorMI system is based on 10 predictors, including left ventricular systolic dysfunction, type of stent used, Killip classification, renal insufficiency, history of stroke, regional wall motion on echocardiography, body mass index, patient age, prior coronary heart disease, and the presence of diabetes mellitus. The KorMI system has shown good discrimination performance and better prediction performance compared to the previously reported Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI), Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC), and Global Registry of Acute Coronary Events (GRACE) scores. A notable feature of this new prediction system is that it is not intended for use in a wide range of AMI patients, but was developed only for use in patients receiving optimal therapies according to the contemporary guidelines. A significant number of patients with AMI are not receiving optimal therapies for many reasons, and they are likely to have a poor prognosis compared to optimally-treated patients. However, predicting adverse outcomes is important even among patients receiving guideline-adherent therapies because they do not have the same risk of recurrence or mortality. This kind of approach has a disadvantage in that it cannot be applied to all patients on various spectrums, but it does enable more accurate risk classification within a targeted population of patients. This narrow targeting approach will become more and more common

in the era of precision medicine, which focuses on personalized prediction, prevention and treatment for smaller groups or individuals.³⁾

The KorMI system, as acknowledged by authors, has not been validated with external datasets, so the reported prediction performance might be over-optimistic.¹⁰⁾ Validation of the KorMI system through external datasets is clearly needed. Improvement of the system to predict longer-term prognosis would also be useful, since the current version predicts only one-year adverse outcomes. These limitations not only affect the KorMI system. Many of CVD-predictive and -prognostic tools are of limited clinical use for the same reasons.²⁾ Lack of external validation and short follow-up periods are common shortcomings of Korean studies, since we do not have abundant long-term follow-up data. It is essential to construct a better Korean dataset that will be relevant, representative and include thorough follow-up. Sufficient epidemiological and clinical data are essential to the development of clinically useful models that will predict the risk and prognosis of CVD.

REFERENCES

1. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. *J Am Coll Cardiol* 2017;70:1-25.
[PUBMED](#) | [CROSSREF](#)
2. Kim HC. Clinical utility of novel biomarkers in the prediction of coronary heart disease. *Korean Circ J* 2012;42:223-8.
[PUBMED](#) | [CROSSREF](#)
3. Björnson E, Borén J, Mardinoglu A. Personalized cardiovascular disease prediction and treatment-a review of existing strategies and novel systems medicine tools. *Front Physiol* 2016;7:2.
[PUBMED](#) | [CROSSREF](#)
4. Jee SH, Jang Y, Oh DJ, et al. A coronary heart disease prediction model: the Korean Heart Study. *BMJ Open* 2014;4:e005025.
[PUBMED](#) | [CROSSREF](#)
5. Park GM, Han S, Kim SH, et al. Model for assessing cardiovascular risk in a Korean population. *Circ Cardiovasc Qual Outcomes* 2014;7:944-51.
[PUBMED](#) | [CROSSREF](#)
6. Cho IJ, Sung JM, Chang HJ, Chung N, Kim HC. Incremental value of repeated risk factor measurements for cardiovascular disease prediction in middle-aged Korean adults: results from the NHIS-HEALS (National Health Insurance System-National Health Screening Cohort). *Circ Cardiovasc Qual Outcomes* 2017;10:e004197.
[PUBMED](#) | [CROSSREF](#)
7. Kim HK, Jeong MH, Ahn Y, et al. A new risk score system for the assessment of clinical outcomes in patients with non-ST-segment elevation myocardial infarction. *Int J Cardiol* 2010;145:450-4.
[PUBMED](#) | [CROSSREF](#)
8. Kim HK, Jeong MH, Ahn Y, et al. Hospital discharge risk score system for the assessment of clinical outcomes in patients with acute myocardial infarction (Korea Acute Myocardial Infarction Registry [KAMIR] score). *Am J Cardiol* 2011;107:965-971.e1.
[PUBMED](#) | [CROSSREF](#)
9. Lee JH, Bae MH, Yang DH, et al. Prognostic value of the age, creatinine, and ejection fraction score for 1-year mortality in 30-day survivors who underwent percutaneous coronary intervention after acute myocardial infarction. *Am J Cardiol* 2015;115:1167-73.
[PUBMED](#) | [CROSSREF](#)
10. Song PS, Ryu DR, Kim MJ, et al. Risk scoring system to assess outcomes in patients treated with contemporary guideline-adherent optimal therapies after acute myocardial infarction. *Korean Circ J* 2018;48:492-504.
[CROSSREF](#)